Company Nymox Pharmaceutical Corporation
Equities
NYMXF
BSP733981026
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.36 USD | -14.29% | -10.00% | -38.98% |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Paul Averback
CEO | Chief Executive Officer | 73 | 95-05-29 |
Patrick Doody
BRD | Director/Board Member | - | 23-07-11 |
Director/Board Member | - | 23-03-20 | |
Suresh Kalbag
PRN | Corporate Officer/Principal | - | - |
General Counsel | - | 20-02-05 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
David S. Morse
BRD | Director/Board Member | 67 | 06-06-07 |
Paul Averback
CEO | Chief Executive Officer | 73 | 95-05-29 |
Director/Board Member | 88 | 15-06-30 | |
Director/Board Member | - | 23-03-20 | |
Patrick Doody
BRD | Director/Board Member | - | 23-07-11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 93,265,000 | 54,049,529 ( 57.95 %) | 0 | 57.95 % |
Company contact information
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
-38.98% | 39.21M | |
+8.21% | 45.97B | |
+53.63% | 43.93B | |
+10.00% | 42.34B | |
-8.59% | 28.27B | |
+16.14% | 27.18B | |
-19.77% | 19.44B | |
+13.72% | 13.83B | |
+31.83% | 12.4B | |
+9.60% | 11.45B |
- Stock
- Equities
- Stock Nymox Pharmaceutical Corporation - OTC Markets
- Company Nymox Pharmaceutical Corporation